preclinical news from FierceBiotech
NewsSpectrum sells off generic drugs
Specturm Pharmaceuticals has sold its abbreviated NDAs for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Read more...
ALSO NOTED: Meda buys late-stage drugs;Debiopharm licenses peptide;and much more...
> How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At Read more...
Inotek closes facilities, shakes up executive staff
There's a shakeup under way at Inotek. The Beverly, MA-based developer says it is closing several international sites and a pilot manufacturing facility in Israel as it focuses all of its efforts on Read more...
ALSO NOTED: Dendreon shares jump on investment deal; Iomai in pact with Merck; Foundation antes millions for MS leads; and much
> Schering-Plough has proven quick on the layoff trigger. The company announced a plan to cut costs by $1.5 billion by 2012 in the wake of the latest round of Vytorin controversy. Roughly 5,500 Read more...
SGX shares slide on report of early-stage toxicity
Shares of SGX Pharmaceuticals were sliding this morning on the news that its lead cancer therapy Read more...
Dutch biotech gains $34M for clinical work
The Dutch biotech PanGenetics has rounded up $34 million in venture backing for the clinical development of two antibody programs. The round was led by Edmond de Rothschild Investment Partners with Read more...
Q Therapeutics raises $15M
Salt Lake City-based Q Therapeutics has raised $15 million in a second round of financing. The company is developing cell-based therapies for the central nervous system. It is currently running Read more...
Speculation mounts over prospective CeNeS buyer
Speculation over the prospective acquisition of CeNeS continued to mount as the company's shares Read more...
Bridge Labs gain $18M in funds, expands in China
Gaithersburg, MD-based Bridge Laboratories is blueprinting an expansion of its Beijing lab space after winning $18 million in new venture backing. The company announced the funding along with its new Read more...
Sirtris causes stir with positive trial data
Sirtris grabbed some headlines at the JP Morgan gathering in San Francisco with its Read more...
| Press ReleasesPRESS RELEASE: Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Preclinical Data Show Lasting Anti-Tumor Effect of Novel Drug Candidate SAN DIEGO -- Hollis-Eden Pharmaceuticals, Read more... PRESS RELEASE: FermaVir Announces Positive Data from Recent Preclinical Studies of FV-100FermaVir Announces Positive Data from Recent Preclinical Studies of FV-100 FermaVir Pharmaceuticals, Inc. today announced positive results from preclinical studies evaluating FV-100, a highly potent, Read more... |
Get more preclinical coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets